Cargando…
Fatal acute-on-chronic liver failure following camrelizumab for hepatocellular carcinoma with HBsAg seroclearance: a case report and literature review
In the last few years, immune checkpoint inhibitors (ICIs) have become major therapeutic agents for the treatment of advanced hepatocellular carcinoma (HCC). However, immunotherapy can activate hepatitis B virus (HBV), and immune clearance may lead to liver failure and even life-threatening conditio...
Autores principales: | Li, Fenghui, Wang, Tao, Tang, Fei, Liang, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461443/ https://www.ncbi.nlm.nih.gov/pubmed/37644988 http://dx.doi.org/10.3389/fmed.2023.1231597 |
Ejemplares similares
-
Evaluation of HBsAg Seroclearance in Patients with Hepatitis B
por: Taşkın, Mehmet Can, et al.
Publicado: (2022) -
Prediction Model of HBsAg Seroclearance in Patients with Chronic HBV Infection
por: Cao, Jing, et al.
Publicado: (2020) -
Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
por: Seto, Wai-Kay, et al.
Publicado: (2012) -
The Role of Steatosis in HBsAg Seroclearance for Patients with Chronic Hepatitis B Infection: Fact or Fiction?
por: Fung, James, et al.
Publicado: (2012) -
Host Genetic Factors Affecting Spontaneous HBsAg Seroclearance in Chronic Hepatitis B Patients
por: Cheng, Huei-Ru, et al.
Publicado: (2013)